TX-MAVENIR
6.12.2023 16:20:38 CET | Business Wire | Press release
Pardeep Kohli, CEO of Mavenir, the Network Software Provider building the future of networks with cloud-native solutions that run on any cloud, has today welcomed the new ranking by global technology intelligence company ABI Research that recognizes Mavenir as the leading vendor in Open Radio Access Network (Open RAN) solutions. In ABI Research’s detailed and independent Competitive Assessment vendor matrix, Mavenir tops all three ranking categories – market leadership, innovation and implementation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231206233989/en/
ABI Research Open RAN Vendor Ranking November 2023 (Graphic: Business Wire)
Mavenir is classed as the leading innovator in the Open RAN space with an impressive score of 81.5 out of 100, while its achievement of 84.5 out of 100 in the implementation criteria reflects Mavenir’s central role in accelerating Open RAN deployments globally. These key rankings position Mavenir as the overall global market leader for Open RAN in the ABI Research assessment framework.
Commenting on Mavenir’s stand-out performance in the global vendor analysis, Mavenir CEO Pardeep Kohli said: “I wholeheartedly welcome this recognition of our market leadership by ABI Research, following a robust and impartial assessment of both new and incumbent players. This pole-position ranking – delivered through ABI Research’s respected and transparent process – is a significant endorsement of our dedicated mission to create the market conditions, forge the industry partnerships and deliver the technology innovation to accelerate ubiquitous and large-scale Open RAN deployments, generating powerful gains for operators and users alike.”
Using a rigorous and thorough assessment framework, ABI Research has evaluated the leading Open RAN vendors to provide a comprehensive and authoritative picture of the competitive dynamics of the Open RAN vendor ecosystem. The core areas of analysis span ten criteria, segmented across innovation and implementation clusters – including R&D activities, O-RAN Alliance contributions, support for mMIMO, recent commercial momentum, product portfolio, geographical coverage, partnerships and memberships, PoCs/trials/testing, energy efficiency commitments and brownfield deployments – concluding with an in-depth profile of the implementation and innovation strategies of the major market players.
Saqlain Ali, Senior Analyst at ABI Research remarked: “Mavenir ranked overall leader in the competitor ranking and earned the top spots for both innovation and implementation. Mavenir has demonstrated its role as a leading Open RAN vendor due to its end-to-end cloud-native software and hardware and O-RAN Alliance-compliant solutions.”
He added: “Mavenir has made significant efforts to accelerate Open RAN deployments in partnerships with other mobile, chipset vendors, and cloud providers to validate its Open RAN portfolio for multi-vendor deployments. Mavenir’s customer base is diverse, with Mavenir serving 300+ CSPs in more than 120 countries.”
The report authors highlight several areas where Mavenir is demonstrating its role as a leading industry innovator in the Open RAN domain, including its provision of end-to-end cloud-native software and hardware solutions with a comprehensive portfolio covering the core, edge and Open RAN. Further emphasized in the framework are Mavenir’s open and fully virtualized RAN (vRAN), its O-RAN Alliance-compliant solution designed to support Open RAN Functional Split (FS) options, plus Mavenir’s OpenBeam™ mMIMO portfolio, which supports both the 3rd Generation Partnership Project (3GPP) and O-RAN Alliance-compliant radios.
Mavenir’s clear commercial momentum during 2023 is a key factor in its top-ranking performance, including its announcement of multiple successful trials and new strategic partnerships with CSPs, cloud providers, and chipset vendors. The assessors particularly note the expansion of Mavenir’s geographical coverage in supporting major mobile operators with Open RAN deployment. Finally, the report draws attention to the considerable breadth of Mavenir’s partner ecosystem, plus its active collaboration with cloud providers, chipset vendors, mobile vendors, and operators to perform Open RAN integration and interoperability testing.
Notes to editors:
- ABI Research, Open RAN Vendor Assessment: Mavenir
© 2023 ABI Research. Distributed with permission of ABI Research. ABI Research Competitive Ranking, Open RAN Portfolio: November 2023
About ABI Research:
ABI Research is a global technology intelligence firm delivering actionable research and strategic guidance to technology leaders, innovators, and decision makers around the world. Our research focuses on the transformative technologies that are dramatically reshaping industries, economies, and workforces today.
For more information about ABI Research’s services, contact us at +1.516.624.2500 in the Americas, +44.203.326.0140 in Europe, +65.6592.0290 in Asia-Pacific, or visit www.abiresearch.com.
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231206233989/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom